File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.2147/COPD.S440895
- Scopus: eid_2-s2.0-85182544120
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation
Title | Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation |
---|---|
Authors | |
Keywords | asthma bronchiectasis COPD COVID-19 interstitial lung disease molnupiravir nirmatrelvir-ritonavir |
Issue Date | 9-Jan-2024 |
Publisher | Taylor and Francis Group |
Citation | International Journal of Chronic Obstructive Pulmonary Disease, 2024, v. 19, p. 77-86 How to Cite? |
Abstract | Introduction: Nirmatrelvir-ritonavir (NMV-r) and molnupiravir (MOL) were developed as out-patient anti-viral for mild COVID-19. There was limited data on their role in treating COVID-19 for hospitalized patients, especially among adult patients who are unvaccinated and had chronic respiratory diseases. |
Persistent Identifier | http://hdl.handle.net/10722/339693 |
ISSN | 2013 Impact Factor: 2.732 2020 SCImago Journal Rankings: 1.394 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwok, Wang Chun | - |
dc.contributor.author | Tam, Terence | - |
dc.contributor.author | Ho, James | - |
dc.contributor.author | Lam, David Chi Leung | - |
dc.contributor.author | Ip, Mary Sau-Man | - |
dc.contributor.author | Ho, Pak Leung | - |
dc.date.accessioned | 2024-03-11T10:38:38Z | - |
dc.date.available | 2024-03-11T10:38:38Z | - |
dc.date.issued | 2024-01-09 | - |
dc.identifier.citation | International Journal of Chronic Obstructive Pulmonary Disease, 2024, v. 19, p. 77-86 | - |
dc.identifier.issn | 1176-9106 | - |
dc.identifier.uri | http://hdl.handle.net/10722/339693 | - |
dc.description.abstract | <p><strong>Introduction:</strong> Nirmatrelvir-ritonavir (NMV-r) and molnupiravir (MOL) were developed as out-patient anti-viral for mild COVID-19. There was limited data on their role in treating COVID-19 for hospitalized patients, especially among adult patients who are unvaccinated and had chronic respiratory diseases.<br><strong>Methods:</strong> A territory-wide retrospective study was conducted in Hong Kong to compare the efficacy of NMV-r and MOL against COVID-19 in unvaccinated adult patients with asthma, chronic obstructive pulmonary disease, bronchiectasis and interstitial lung diseases presenting with moderate COVID-19 from 16th February 2022 to 15th March 2023.<br><strong>Results:</strong> A total of 1354 patients were included, 738 received NMV-r and 616 received MOL. NMV-r was more effective in reducing 90-day mortality with adjusted hazard ratios (aHR) of 0.508 (95% confidence interval [CI] = 0.314– 0.822, p = 0.006). Patients who received NMV-r also had significantly shorter length of stay (LOS) than those receiving MOL, with median LOS of 4 (Interquartile range [IQR] = 2– 7) for NMV-r and 6 (IQR = 3– 10) for MOL (p-value < 0.001). There was no statistically significant difference in the development of respiratory failure and severe respiratory failure in the two groups.<br><strong>Discussion:</strong> NMV-r was more effective than MOL among unvaccinated adults with chronic respiratory diseases who were hospitalized for moderate COVID-19 without hypoxaemia on admission.<br></p> | - |
dc.language | eng | - |
dc.publisher | Taylor and Francis Group | - |
dc.relation.ispartof | International Journal of Chronic Obstructive Pulmonary Disease | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | asthma | - |
dc.subject | bronchiectasis | - |
dc.subject | COPD | - |
dc.subject | COVID-19 | - |
dc.subject | interstitial lung disease | - |
dc.subject | molnupiravir | - |
dc.subject | nirmatrelvir-ritonavir | - |
dc.title | Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation | - |
dc.type | Article | - |
dc.identifier.doi | 10.2147/COPD.S440895 | - |
dc.identifier.scopus | eid_2-s2.0-85182544120 | - |
dc.identifier.volume | 19 | - |
dc.identifier.spage | 77 | - |
dc.identifier.epage | 86 | - |
dc.identifier.eissn | 1178-2005 | - |
dc.identifier.issnl | 1176-9106 | - |